These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10048506)

  • 1. Stability of captopril in invert sugar solution.
    Sam WJ; Ho PC
    J Clin Pharm Ther; 1998 Dec; 23(6):451-6. PubMed ID: 10048506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations.
    Liu J; Chan SY; Ho PC
    J Clin Pharm Ther; 1999 Apr; 24(2):145-50. PubMed ID: 10380067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of formulation properties on chemical stability of captopril in aqueous preparations.
    Kristensen S; Lao YE; Brustugun J; Braenden JU
    Pharmazie; 2008 Dec; 63(12):872-7. PubMed ID: 19177902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids.
    Lye MY; Yow KL; Lim LY; Chan SY; Chan E; Ho PC
    Am J Health Syst Pharm; 1997 Nov; 54(21):2483-7. PubMed ID: 9359955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles.
    Brustugun J; Lao YE; Fagernaes C; Braenden J; Kristensen S
    Am J Health Syst Pharm; 2009 Oct; 66(19):1722-5. PubMed ID: 19767378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of extemporaneously prepared saquinavir formulations.
    Tan LK; Thenmozhiyal JC; Ho PC
    J Clin Pharm Ther; 2003 Dec; 28(6):457-63. PubMed ID: 14651667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
    Casas M; Álvarez J; Lucero MJ
    Pharm Dev Technol; 2015 May; 20(3):271-8. PubMed ID: 24279906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of captopril in SyrSpend SF.
    Geiger CM; Sorenson B; Whaley PA
    Int J Pharm Compd; 2013; 17(4):336-8. PubMed ID: 24261148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antioxidants and anti-irritants on the stability, skin irritation and penetration capacity of captopril gel.
    Huang YB; Tsai YH; Chang JS; Liu JC; Tsai MJ; Wu PC
    Int J Pharm; 2002 Jul; 241(2):345-51. PubMed ID: 12100862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of captopril in some aqueous systems.
    Pramar Y; Das Gupta V; Bethea C
    J Clin Pharm Ther; 1992 Jun; 17(3):185-9. PubMed ID: 1639881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom.
    Mulla H; Tofeig M; Bu'Lock F; Samani N; Pandya HC
    Arch Dis Child; 2007 May; 92(5):409-11. PubMed ID: 17363396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix type transdermal therapeutic system containing captopril: formulation optimization, in vitro and ex vivo characterization.
    Kerimoğlu O; Keskin E; Dortunç B; Anah S
    Acta Pol Pharm; 2013; 70(2):291-300. PubMed ID: 23614285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkaline degradation of invert sugar from molasses.
    Yang BY; Montgomery R
    Bioresour Technol; 2007 Nov; 98(16):3084-9. PubMed ID: 17222551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stability study of an aqueous formulation of captopril at 1 mg/ml].
    Escribano García MJ; Torrado Durán S; Torrado Durán JJ
    Farm Hosp; 2005; 29(1):30-6. PubMed ID: 15773800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of captopril in tap water.
    Pereira CM; Tam YK
    Am J Hosp Pharm; 1992 Mar; 49(3):612-5. PubMed ID: 1598937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study.
    Curtivo CP; Funghi NB; Tavares GD; Barbosa SF; Löbenberg R; Bou-Chacra NA
    Pharm Dev Technol; 2015 May; 20(3):345-51. PubMed ID: 24344991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro interactions of captopril with NSAID's.
    Sultana N; Arayne MS; Quraishi RU
    Pak J Pharm Sci; 2006 Jul; 19(3):202-7. PubMed ID: 16935827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the SeDeM diagram expert system for the formulation of Captopril SR matrix tablets by direct compression.
    Saurí J; Millán D; Suñé-Negre JM; Pérez-Lozano P; Sarrate R; Fàbregas A; Carrillo C; Miñarro M; Ticó JR; García-Montoya E
    Int J Pharm; 2014 Jan; 461(1-2):38-45. PubMed ID: 24284019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting kinetic spectrophotometric determination of captopril, an angiotensin-converting enzyme inhibitor, in a multi-pumping flow system.
    Prior JA; Santos JL; Lima JL
    Anal Chim Acta; 2007 Sep; 600(1-2):183-7. PubMed ID: 17903482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.